Fulcrum Therapeutics (FULC)
(Real Time Quote from BATS)
$7.23 USD
+0.09 (1.26%)
Updated Apr 29, 2024 10:24 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
FULC 7.23 +0.09(1.26%)
Will FULC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FULC
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates
Other News for FULC
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
10 Health Care Stocks Whale Activity In Today's Session
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)